New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

WESTLAKE VILLAGE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The updated labeling provides a new conversion chart for starting dosages when switching patients from subcutaneous mealtime insulin to Afrezza. The Food and Administration (FDA) has approved updated ...

ATLANTA - After living for more than 20 years with type 1 diabetes, "My entire life, as I know it with diabetes, has changed," says Laura Kronen. Laura Kronen has discovered Afrezza, insulin you ...

Sanofi and MannKind Corporation MNKD +24.23% announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) ...

The new diabetes test helps identify patients with type 1 diabetes Afrezza can be used for the improvement of glycemic control in adult patients with diabetes mellitus. The FDA announced the approval ...

MannKind bulls and bears won't have to wait too much longer to see how well the company's inhaled insulin drug, Afrezza, will perform on the market. During MannKind's presentation at the JP Morgan ...

A major catalyst window opens for this biopharma stock with Q1 earnings due on May 6, and two key FDA decisions in May and July.

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured ...